Brief Article
Copyright ©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 7, 2010; 16(37): 4691-4696
Published online Oct 7, 2010. doi: 10.3748/wjg.v16.i37.4691
Table 1 Baseline characteristics of lamivudine treated patients
Lamivudine resistance (n = 111)Lamivudine no resistance (n = 117)P value
Male, n (%)81 (73.0)86 (73.5)0.928
Chinese, n (%)107 (96.4)108 (92.3)0.183
Age, yr [mean (95%CI)]46.5 (44-49)49.6 (47-52)0.080
Cirrhosis, n (%)36 (32.4)35 (29.9)0.682
Baseline bilirubin, μmol/L [mean (95% CI)]19 (15-23)30 (17-43)0.124
Baseline albumin, g/L [mean (95% CI)]36 (34-37)37 (36-38)0.326
Baseline ALT, U/L [mean (95% CI)]175 (131-219)269 (191-348)0.038
Baseline AST, U/L [mean (95% CI)]132 (88-176)197 (132-262)0.100
HBeAg positive, n (%)77 (70.0)42 (35.9)< 0.001
Baseline log HBV DNA, IU/mL [mean (95% CI)]6.5 (6.3-6.8)5.7 (5.4-6.1)< 0.001
Baseline abnormal ALT, n (%)59 (53.15)65 (55.55)0.716
Patients with (n = 111) and without lamivudine resistance (n = 117). ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HBV: Hepatitis B virus; HBeAg: Hepatitis B "e" antigen.